VA launches trial to test GLP-1 medication for alcohol use disorder in veterans
The Department of Veterans Affairs has initiated a clinical trial to investigate the potential of semaglutide in treating alcohol use disorder in veterans. This condition affects over 400,000 veterans nationwide. Semaglutide, known by brand names Ozempic and Wegovy, is currently approved for Type 2 diabetes and chronic weight management.
Researchers are exploring its possible effects on the brain's reward system. Further details about the trial, including its methodology and expected outcomes, are available from the Department of Veterans Affairs. The department advises veterans against self-medicating with GLP-1 medications without consulting a healthcare provider.
Related Health stories
Virtual reality pain treatment expands for veterans
The Department of Veterans Affairs is expanding access to a U.S. Food and Drug Administration-authorized virtual reality (VR) therapy design
Live Whole Health #320: You deserve a break
Do you spend hours jumping between screens, messages and tasks during the day? Over time, this can make your mind tired and your body stiff.
First in VA to receive cutting-edge epilepsy treatment
A groundbreaking laser procedure offers a safer option for epilepsy treatment Back in 1980, when Robert Lindemann decided to enlist in the A